000835091 001__ 835091
000835091 005__ 20210129230819.0
000835091 0247_ $$2doi$$a10.1001/jamaneurol.2017.0892
000835091 0247_ $$2ISSN$$a0003-9942
000835091 0247_ $$2ISSN$$a0375-8540
000835091 0247_ $$2ISSN$$a1538-3687
000835091 0247_ $$2ISSN$$a2168-6149
000835091 0247_ $$2ISSN$$a2168-6157
000835091 0247_ $$2Handle$$a2128/14936
000835091 0247_ $$2WOS$$aWOS:000405077100015
000835091 0247_ $$2altmetric$$aaltmetric:20705924
000835091 0247_ $$2pmid$$apmid:28558099
000835091 037__ $$aFZJ-2017-04959
000835091 041__ $$aEnglish
000835091 082__ $$a610
000835091 1001_ $$0P:(DE-HGF)0$$aFarrell, Michelle E.$$b0
000835091 245__ $$aAssociation of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults
000835091 260__ $$aChicago, Ill.$$bAmerican Medical Association$$c2017
000835091 3367_ $$2DRIVER$$aarticle
000835091 3367_ $$2DataCite$$aOutput Types/Journal article
000835091 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1500536913_11986
000835091 3367_ $$2BibTeX$$aARTICLE
000835091 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000835091 3367_ $$00$$2EndNote$$aJournal Article
000835091 520__ $$aImportance  Presently, the clinical standard for reporting the results of an amyloid positron emission tomography scan is to assign a dichotomous rating of positive or negative for the presence of amyloid. In a 4-year longitudinal study, we investigated whether using a continuous measure of the magnitude of baseline amyloid burden would provide valuable information about the rate of future cognitive decline over the subsequent 4 years compared with a dichotomous measure in middle-aged and older adults.Objective  To examine whether a continuous, dose-response relationship between amyloid burden and cognitive decline was present among middle-aged and older adults.Design, Setting, and Participants  This cohort study included 174 participants from the Dallas Lifespan Brain Study who were 40 to 89 years old at the beginning of the study, were cognitively normal at baseline (a Mini-Mental State Examination score of 26 or higher) with no history of neurological or psychiatric disorders, and had completed amyloid imaging ([18F]-florbetapir) at baseline and cognitive assessments at baseline and a 4-year follow-up. Continuous amyloid burden was measured as the mean cortical standardized uptake value ratio (SUVR) at baseline.Main Outcomes and Measures  Linear mixed models assessed the effect of increasing baseline amyloid over time (SUVR × time interaction) on episodic memory, reasoning, processing speed, vocabulary, and Mini-Mental State Examination performance. Age, sex, education, apolipoprotein ε4, and the random effect of intercepts were included as covariates.Results  The mean (SD) age for all participants (n = 174) was 66.44 (11.74) years, and 65 participants (37%) were men. The primary analyses yielded significant SUVR × time interactions in episodic memory, processing speed, vocabulary, and Mini-Mental State Examination performance, but not in reasoning performance. Higher baseline SUVR projected greater cognitive decline over 4 years. When controlling for variance related to a dichotomized positive/negative classification, most effects on cognition remained. Dichotomized amyloid status alone yielded fewer significant effects of amyloid on cognitive decline than continuous SUVR. Among amyloid-positive participants, increasing baseline SUVR predicted an increasing decline in episodic memory, but other effects on cognition were more limited. Finally, higher baseline amyloid burden among middle-aged adults was related to changes in vocabulary, with the effect driven by 3 apolipoprotein ε4 homozygotes.Conclusions and Relevance  These results suggest that the magnitude of amyloid burden at baseline is associated with the rate of cognitive decline over 4 years and potentially provides important information about the rate of future cognitive decline that is not available from a dichotomous positive/negative categorization.
000835091 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000835091 588__ $$aDataset connected to CrossRef
000835091 7001_ $$0P:(DE-HGF)0$$aKennedy, Kristen M.$$b1
000835091 7001_ $$0P:(DE-HGF)0$$aRodrigue, Karen M.$$b2
000835091 7001_ $$0P:(DE-HGF)0$$aWig, Gagan$$b3
000835091 7001_ $$0P:(DE-Juel1)166265$$aBischof, Gérard N.$$b4
000835091 7001_ $$0P:(DE-HGF)0$$aRieck, Jennifer R.$$b5
000835091 7001_ $$0P:(DE-HGF)0$$aChen, Xi$$b6
000835091 7001_ $$0P:(DE-HGF)0$$aFestini, Sara B.$$b7
000835091 7001_ $$0P:(DE-HGF)0$$aDevous, Michael D.$$b8
000835091 7001_ $$0P:(DE-HGF)0$$aPark, Denise C.$$b9$$eCorresponding author
000835091 773__ $$0PERI:(DE-600)2701924-X$$a10.1001/jamaneurol.2017.0892$$gVol. 74, no. 7, p. 830 -$$n7$$p830 - 838$$tJAMA neurology$$v74$$x2168-6149$$y2017
000835091 8564_ $$uhttps://juser.fz-juelich.de/record/835091/files/jamaneurology_Farrell_2017_oi_170026.pdf$$yOpenAccess
000835091 8564_ $$uhttps://juser.fz-juelich.de/record/835091/files/jamaneurology_Farrell_2017_oi_170026.gif?subformat=icon$$xicon$$yOpenAccess
000835091 8564_ $$uhttps://juser.fz-juelich.de/record/835091/files/jamaneurology_Farrell_2017_oi_170026.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000835091 8564_ $$uhttps://juser.fz-juelich.de/record/835091/files/jamaneurology_Farrell_2017_oi_170026.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000835091 8564_ $$uhttps://juser.fz-juelich.de/record/835091/files/jamaneurology_Farrell_2017_oi_170026.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000835091 8564_ $$uhttps://juser.fz-juelich.de/record/835091/files/jamaneurology_Farrell_2017_oi_170026.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000835091 909CO $$ooai:juser.fz-juelich.de:835091$$pdnbdelivery$$pVDB$$pdriver$$popen_access$$popenaire
000835091 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166265$$aForschungszentrum Jülich$$b4$$kFZJ
000835091 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000835091 9141_ $$y2017
000835091 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000835091 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000835091 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA NEUROL : 2015
000835091 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000835091 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000835091 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000835091 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000835091 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJAMA NEUROL : 2015
000835091 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000835091 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000835091 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000835091 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000835091 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000835091 920__ $$lyes
000835091 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000835091 980__ $$ajournal
000835091 980__ $$aVDB
000835091 980__ $$aUNRESTRICTED
000835091 980__ $$aI:(DE-Juel1)INM-3-20090406
000835091 9801_ $$aFullTexts